Summary: There is little data on the amount of time patients and families typically wait for pathology results when pediatric malignancy is suspected. The purpose of this study was to determine the average waiting period after diagnostic intervention for pediatric cancer. Pathology reports were reviewed for pediatric patients who had their initial diagnosis and were followed in the Division of Hematology/Oncology from 2007 through 2010. The average turnaround time (TAT) for all pathology (n = 266) was 6.9 days. The TAT for pathology results according to diagnosis was 10.1 days for CNS tumors (n = 59), 9.7 days for sarcomas (n = 40), 5.4 days for lymphomas (n = 31), 5.4 days for neuroblastoma (n = 13), 7.3 days for kidney tumors (n = 11), 7.2 days for thyroid tumors (n = 7), 9.4 days for ovarian tumors (n = 7), 7.0 days for schwannomas/neurofibromas (n = 5), 5.7 days for testicular tumors (n = 3), 5.0 days for hepatoblastoma (n = 3), and 7.0 days for nasopharyngeal carcinomas (n = 2). Overall the TAT for leukemia was 3.1 days (n = 76), with diagnosis by flow cytometry taking 1.2 days and results by bone marrow biopsy taking 4.0 days. The TAT for pediatric oncology pathology after diagnostic intervention varies according to diagnosis. The hope is that this information will better prepare patients and families for the agonizing waiting period associated with diagnosis.
T he diagnosis and treatment of cancer in a child is such traumatic experience that families have been found to have an increased incidence of posttraumatic stress symptoms and posttraumatic stress disorder. 1, 2 Many have supported the idea that the stress of childhood cancer can negatively affect both parent and the child's ability to function, as well impact adherence to medical therapy. 3 There have been a number of studies looking into the sources of stress that come with the diagnosis of cancer. A prior study examining depression and anxiety associated with evaluation for prostate cancer showed that the most stressful period of time is awaiting biopsy results. 4 Likewise, women with breast cancer reported significantly higher levels of uncertainty and anxiety during the diagnostic period. 5 In fact, uncertainty about final diagnosis after large-core breast biopsy was associated with substantial biochemical distress as indicated by abnormal cortisol levels similar to those in women with known malignant disease. 6 The stress borne from the uncertainty of diagnosis has not been thoroughly explored in pediatric oncology. But extrapolating from what is known in adult patients, the time from biopsy to final diagnosis likely contributes significant stress for the patient and family. Knowledge of when a final diagnosis will likely be available could help mitigate this stress.
In an effort to help establish realistic expectations for families and patients, the purpose of this study was to establish the time from biopsy to final diagnosis for pediatric patients with expected malignancy.
METHODS
This study was conducted as a quality improvement project and received approval of the Montefiore IRB committee. The records for patients treated in the Division of Hematology/Oncology at Montefiore Medical Center from 2007 to April 2010 were surveyed for this study. Potentially eligible patients were gathered from appointment and imaging schedules. The patients included in this study had their initial diagnostic workup and diagnosis at Montefiore. Pathology consisted of biopsies, surgical resections, and flow cytometry. No cases of relapse were included in this study. The pathology records of eligible patients were reviewed for date of pathology accessioning and date of final pathology results. The number of calendar days from pathology accessioning to final pathology report was calculated and reported as turnaround time (TAT). In cases of leukemia where both flow cytometry and bone marrow biopsies were performed, the earliest documented results in the medical record were used to determine this time period.
The mean TAT and SD (s) was calculated for all pathology and then subdivided according to final diagnosis. All statistical calculations were performed using Microsoft Excel.
Patients were excluded if they already had an existing diagnosis at the time of available pathology reports. Patients were also excluded from the study if initial reports were modified for any reason after diagnosis, as the date of modification, was reported on the pathology reports as the date of final pathology results and obscured the true TAT.
RESULTS
A total of 490 records for patients seen in the Division of Pediatric Hematology/Oncology at the Children's Hospital at Montefiore were reviewed. These patients were seen in clinic from January 2007 to April 2010. Two hundred sixty-six of 490 patients had available pathology reports that corresponded to their initial oncologic diagnosis at Montefiore. Pathology reports were either not available for the remaining patients or these patients had their initial diagnosis at another institution before coming to Montefiore for therapy. Sixteen pathology reports were excluded because of modification of initial pathology results, which obscured the date of diagnosis. The excluded pathology reports included 1 with leukemia, 3 with lymphoma, 2 with Wilms tumor, 6 with CNS tumors, and 4 with sarcoma. The reasons for report modification after initial diagnosis included additional pathology stains, electron microscopy, cytogenetic studies, and clerical errors.
Overall for the 266 patients included in this study the mean TAT from accessioning to diagnosis was 6.9 days (s = 6.2). Twenty-five percent of final pathology reports were completed by 3 days. Forty-five percent were completed by 5 days. Ninety percent were completed by 14 days. The mean TAT and SD for cancer subtypes is shown in Table 1 .
DISCUSSION
The wait for a diagnosis can be agonizing and is known to take a tremendous toll on both patients and their families. [1] [2] [3] [4] [5] [6] As physicians, we are shouldered with the arduous task of guiding families through the diagnostic period, as they look to us for answers. Although pathology results are not the only important aspect of a diagnostic workup, for families it often does answer what many would consider one of the most important questions of all: "Does my child have cancer?" Regardless of the answer, the agony of the wait is no less grueling. And if the answer is unfortunately "yes," then this is only the start of a long, complex process leading to discussions regarding treatment options and prognosis.
The goal of this study was to determine the TAT for pediatric oncologic pathology while seeing how the time to pathologic confirmation differed based on cancer type. The published data on pathology TAT in the last 15 years has been sparse and to date there is a lack of data on the TAT for malignant pathology. However, it is our hope that our results can provide patients and their families with reasonable expectations about when the next phase of discussions could begin and better prepare them for the challenges of the diagnostic period.
In addition to its potential use as a tool in communication with patients and families, we felt that this data has the potential to stimulate interdisciplinary discussions on TAT in this subpopulation of patients and pathology. Previous studies have focused on nononcologic anatomic pathology, but highlighted that differences exist due to variations in specimen preparation, consultations, presence of pathology trainees, as well as being affected by specimen volume and institutional size. 7, 8 Although it is difficult to compare our current data to previously reported, and now outdated studies, our results demonstrated that the TAT for pediatric oncology pathology was delayed compared with available data on complex pathology. In 1996, Zarbo et al 7 reported that 78% of special-handled complex pathology was completed in 3 days and 98.5% was completed by 9 days, compared with our study, which showed only 25% of oncology pathology was completed by 3 days and 90% by 14 days. A recent study by Patel and colleagues demonstrated differences in TAT between oncologic and nononcologic pathology. This single institution study looking at nonbiopsy surgical pathology, found that the diagnosis of malignancy was associated with significantly increased TAT. 9 Together this serves to highlight the paucity of data on TAT for malignant pathology and emphasize the need to better quantify the expected waiting time for these results. Oncologic pathology is an important subgroup of surgical pathology. Rapid results are required due to gravity of the diagnosis and rapid treatment plan that is enacted, but accuracy obviously takes precedence. The exact reasons for these additional delays have not been reported, but the overall increased complexity of these specimens is surely to be a contributing factor. Furthermore, there are obviously grave consequences associated with incorrectly identifying oncologic specimens. As such, the majority of specimens with significantly prolonged TATs in each diagnostic group in our study were delayed by secondary consultations to pathologists outside our center. Additional studies will likely be needed to identify what is contributing to this increase in TAT of malignant pathology and whether anything could potentially be done to decrease the analytic component of this TAT.
Although the data acquired is informative, there were a number of limitations and weaknesses to this study. For the purposes of this study we elected to focus on pathology results that would serve to provide definitive initial diagnosis. However, there are additional pathology results that we did not include that could be extremely important to staging and/or treatment decisions. Cytogenetic studies, although a vital part of prognosis and potential treatment targets, were not included in our review, as treatment initiation would not be delayed until this level of diagnostic information is obtained. In addition, frozen section results were also available in some cases, but because these specimens can often be misleading our institution elects to await final pathology if it is clinically tolerable. We also did not account for the type of pathology specimen accessioned (biopsy vs. resection), tissue type, and location, which can all be significant factors in sample processing and analysis. Future studies may want to take all of these into consideration.
Lastly, 1 factor that affects TAT is when specimens arrive in the laboratory for analysis. Specimens that arrive toward the end of the workweek or late in a day could result in longer TAT when compared with similar specimens arriving at more optimal analysis times. Overall, this could lead to increased TATs, but is an undeniably realistic issue and one that we feel should be taken into consideration in discussions with patients and families.
This study is the experience of a single institution, but hopes to highlight the importance of the TAT of pediatric oncology pathology. This wait can be agonizing for patients and families, and every effort should be made to support them and alleviate their stress during this workup. Future studies could analyze how effective this information was in preparing families for the diagnostic workup and how satisfied they were with the pathology TAT during this period. This data could also serve as a future benchmark for other institutions looking to evaluate their own oncology pathology TAT. The number of patients (n), mean number of calendar days from specimen acquisition to diagnosis (TAT), and respective SD (s) for each cancer subtype. *3 patients with ALL diagnosed by non-bone marrow biopsy (1 mediastinal mass, l liver mass, and 1 lymph node).
AFH indicates angiomatoid fibrous histiocytoma; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATRT, atypical teratoid/ rhabdoid tumor; CML, chronic myeloid leukemia; DFSP, dermatofibrosarcoma protuberans; DNET, dysembryoplastic neuroepithelial tumor; DSRCT, desmoplastic small round cell tumor; GBM, glioblastoma multiforme; JPA, juvenile pilocytic astrocytoma; LCH, Langerhans cell histiocytosis; MDS, myelodysplastic syndrome; MFH, malignant fibrous histiocytoma; NHL, non-Hodgkin lymphoma; TAT, turnaround time.
